Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.26
- Piotroski Score 3.00
- Grade Outperform
- Symbol (SRPT)
- Company Sarepta Therapeutics, Inc.
- Price $114.27
- Changes Percentage (3.41%)
- Change $3.77
- Day Low $110.68
- Day High $114.50
- Year High $173.25
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $167.00
- High Stock Price Target $203.00
- Low Stock Price Target $94.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.43
- Trailing P/E Ratio 286.79
- Forward P/E Ratio 286.79
- P/E Growth 286.79
- Net Income $-535,977,000
Income Statement
Quarterly
Annual
Latest News of SRPT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Biotech Stock According to Hedge Funds?
A list of the 10 most promising biotech stocks was recently compiled, featuring Sarepta Therapeutics, Inc. (NASDAQ:SRPT). The biotech sector's growth, market trends, and potential impact of federal in...
By Yahoo! Finance | 1 month ago -
Is Sarepta Therapeutics, Inc. (SRPT) One of the Best Revenue Growth Stocks to Buy According to Analysts?
A recent article analyzes Sarepta Therapeutics, Inc. (NASDAQ: SRPT) against other top revenue growth stocks recommended by analysts. It discusses the impact of recent Fed rate cuts and market trends....
By Yahoo! Finance | 1 month ago -
Sarepta Therapeutics (SRPT): Soaring with Successful Therapies and Cash Flow Positivity
Insider Monkey's recent article highlights the 16 Best Mid Cap Growth Stocks, focusing on Sarepta Therapeutics Inc. (NASDAQ:SRPT)....
By Yahoo! Finance | 2 months ago
